Hostname: page-component-586b7cd67f-tf8b9 Total loading time: 0 Render date: 2024-11-30T20:08:15.988Z Has data issue: false hasContentIssue false
  • English
  • Français

Radiation-induced toxicity in cancer patients with low plasma fibronectin levels

Published online by Cambridge University Press:  11 November 2010

Roxana G. Baluna ,
Clifton D. Fuller ,
Tony Y. Eng ,
Federico L. Ampil  and
Charles R. Thomas Jr.
Roxana G. Baluna*
Affiliation:
Department of Radiology, Radiation Oncology, Louisiana State University Health Science Center, Shreveport, LA, USA
Clifton D. Fuller
Affiliation:
Department of Radiation Oncology, The University of Texas Health Science Center, San Antonio, TX, USA
Tony Y. Eng
Affiliation:
Department of Radiation Oncology, The University of Texas Health Science Center, San Antonio, TX, USA
Federico L. Ampil
Affiliation:
Department of Radiology, Radiation Oncology, Louisiana State University Health Science Center, Shreveport, LA, USA
Charles R. Thomas Jr.
Affiliation:
Department of Radiation Medicine, Oregon Health & Science University, Portland, OR, USA
*
Correspondence to: Roxana G. Baluna, Department of Radiology, Louisiana State University Health Science Center, 1501 Kings Highway, Shreveport, LA 71130, USA. Email: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

The present study was carried out to evaluate the levels of plasma fibronectin (Fn) in cancer patients undergoing radiation therapy (RT) in correlation with outcomes in terms of radiation toxicity. A total of 26 patients with lung and gastrointestinal (GI) cancer, treated with RT were enrolled in this study. Plasma Fn levels were determined before and following a course of RT. The Radiation Therapy Oncology Group (RTOG) criteria were used to determine the grade of RT toxicity. Statistical analysis utilised the nonparametric Mann–Whitney U-test as well as bivariate linear regression. Pre-RT Fn levels were significantly higher in cancer patients without toxicity (median ± SE) (485.0 ± 87 μg/ml) as compared with the levels of plasma Fn in patients with grade I–II RTOG acute toxicity (354.0 ± 74 μg/ml, p = 0.01). No significant difference in Fn levels was found in patients with grade I toxicity compared with patients with grade II toxicity. In addition, low baseline Fn levels (148 and 299 μg/ml) were observed in two lung cancer patients who developed symptomatic pneumonitis during the first 2 months after RT. These preliminary results suggest that low baseline Fn may have potential as a predictive marker for development of RT-induced toxicity.

Keywords

radiation toxicityfibronectinlung cancergastrointestinal cancer
Type
Original Article
Information
Journal of Radiotherapy in Practice , Volume 10 , Issue 1 , March 2011 , pp. 27 - 33
Copyright
Copyright © Cambridge University Press 2011

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Stone, HB, McBride, WH, Colema, CN. Modifying normal tissue damage post-irradiation. Report of Workshop sponsored by the Radiation Research Program, National Cancer Institute, Bethesda, Maryland. Rad Res 2000; 157: 204–223.CrossRefGoogle Scholar
Anscher, MS, Chen, L, Rabbani, Z et al. Recent progress in defining mechanisms and potential targets for prevention of normal tissue injury after radiation therapy. Int J Radiat Oncol Biol Phys 2005; 62: 255–259.CrossRefGoogle ScholarPubMed
De Jaeger, K, Seppenwoolde, Y, Kampinga, H, Boersma, LJ, Belderbos, JS, Lebesque, JV. Significance of plasma transforming growth factor-β levels in radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2004; 58: 1378–1387.CrossRefGoogle ScholarPubMed
Anscher, MS, Kong, FM, Andrews, K et al. Plasma transforming growth factor beta1 as a predictor of radiation pneumonitis 1998. Int J Radiat Oncol Biol Phys 1998; 41: 1029–1035.CrossRefGoogle Scholar
Chen, J, Williams, J, Ding, I et al. Radiation pneumonitis and early circulatory cytokine markers. Semin Radiat Oncol 2002; 12: 26–33.CrossRefGoogle ScholarPubMed
Ishii, Y, Kitamura, S. Soluble intercellular adhesion molecule-1 as an early detection marker for radiation pneumonitis. Eur Respir J 1999; 13: 733–738.CrossRefGoogle ScholarPubMed
Chen, Y, Hyrien, O, Williams, J, Okunieff, P, Smudzin, T, Rubin, P. Interleukin (IL)-1A and IL-6: applications to the predictive diagnostic testing of radiation pneumonitis. Int J Radiat Oncol Biol Phys 2005; 62: 260–266.CrossRefGoogle Scholar
Baluna, RG, Eng, TY, Thomas, CR. Adhesion molecules in radiotherapy. Radiat Res 2006; 166: 819–831.CrossRefGoogle ScholarPubMed
Villani, F, Dell'Oca, I, De Maria, P et al. Lung function and serum concentration of tumor necrosis factor-alpha, interleukin-6 and fibronectin in patients treated with ABVD chemotherapy followed by radiotherapy for mediastinal Hodgkin’s disease. Anticancer Res 1999; 19: 4475–4480.Google ScholarPubMed
Abratt, RP. Lung toxicity following chest irradiation in patients with lung cancer. Lung Cancer 2002; 35: 103–110.CrossRefGoogle ScholarPubMed
Finkelstein, J, Johnston, CJ, Baggs, R, Rubin, P. Early alterations in extracellular matrix and transforming growth factor beta gene expression in mouse lung indicative of late radiation fibrosis. Int J Radiat Oncol Biol Phys 1994; 28: 621–631.CrossRefGoogle ScholarPubMed
Roman, J. Extracellular matrix and lung inflammation. Immunol Res 1996; 15: 163–178.CrossRefGoogle ScholarPubMed
Vignola, AM, Chanez, P, Chiappara, G et al. Release of transforming growth factor-beta (TGF-beta) and fibronectin by alveolar macrophages in airway diseases. Clin Exp Immunol 1996; 106: 114–119.CrossRefGoogle ScholarPubMed
Ruoslahti, E. Fibronectin and its integrin receptors in cancer. Adv Cancer Res 1999; 76: 1–20.CrossRefGoogle ScholarPubMed
Pankov, R, Yamada, KM. Fibronectin at a glance. J Cell Sci 2002; 115: 3861–3863.CrossRefGoogle ScholarPubMed
Saba, TM, Jaffe, E. Plasma fibronectin (opsonic glycoprotein): its synthesis by vascular endothelial cells and role in cardiopulmonary integrity after trauma as related to reticuloendothelial function. Am J Med 1980; 68: 577–594.CrossRefGoogle ScholarPubMed
Briggs, SL. The role of fibronectin in fibroblast migration during tissue repair. J Wound Care 2005; 14: 284–287.CrossRefGoogle ScholarPubMed
Romberger, DJ. Molecules in focus - fibronectin. Int J Biochem Cell Biol 1997; 29: 939–943.CrossRefGoogle Scholar
Zerlauth, G, Wolf, G. Plasma fibronectin as a marker for cancer and other diseases. Am J Med 1984; 77: 685–689.CrossRefGoogle ScholarPubMed
Hegele, A, Heidenreich, A, Kropf, J et al. Plasma levels of cellular fibronectin in patients with localized and metastatic renal cell carcinoma. Tumour Biol 2004; 25: 111–116.CrossRefGoogle ScholarPubMed
Ruelland, A, Kerbrat, P, Clerc, C, Legras, B, Cloarec, L. Level of plasma fibronectin in patients with breast cancer. Clin Chimica Acta 1988; 178: 283–287.CrossRefGoogle ScholarPubMed
Hegele, A, Varga, Z, von Knobloch, R, Olbert, P, Kropf, J, Hofmann, R. Cellular fibronectin plasma and urine levels in human bladder cancer. Eur Urology 2002; 1: 76–77.Google Scholar
Ruiz, MG, Prieto, PJ, Veiga de Cabo, J et al. Plasma fibronectin as a marker of sepsis. Int J Infect Dis 2004; 8: 236–243.Google Scholar
Pence, S, Yilmaz, G, Yilmaz, N et al. Determination of plasma fibronectin and serum C-reactive protein in patients with cerebrovascular events. Int J Clin 2003; 57: 91–95.Google ScholarPubMed
Ohke, M, Tada, S, Kataoka, M, Matsuo, K, Nabe, M, Harada, M. Plasma fibronectin in asthmatic patients and its relation to asthma attack. Acta Med Okayama 2001; 55: 91–96.Google ScholarPubMed
Simo, R, Segura, RM, Garcia-Pascual, L et al. Fibronectin and diabetes mellitus: the factors that influence its plasma concentrations and its usefulness as a marker of late complications. Med Clin 1999; 112: 45–50.Google ScholarPubMed
Ostlund, E, Hansson, LO, Bremme, K. Fibronectin is a marker for organ involvement and may reflect the severity of preeclampsia. Hypertens Pregnancy 2001; 20: 79–87.CrossRefGoogle ScholarPubMed
Liu, XS, Luo, ZH, Yang, ZC, Li, AN. Clinical significance of the changes in serum fibronectin in severely burned patients. Burns 1996; 22: 295–297.CrossRefGoogle ScholarPubMed
Baluna, R, Sausville, E, Stone, MJ, Stetler-Stevenson, MA, Uhr, J, Vitetta, E. Decreases in levels of serum fibronectin predict the severity of vascular leak syndrome in patients treated with ricin A chain-containing immunotoxins. Clin Cancer Res 1996; 2: 1705–1711.Google ScholarPubMed
Bjermer, L, Hallgren, R, Nilsson, K, Franzen, L, Sandstrom, B, Henriksson, R. Radiation-induced increase in hyaluronan and fibronectin in bronchoalveolar lavage fluid from breast cancer patients is suppressed by smoking. Eur Respir J 1992; 5: 785–790.CrossRefGoogle ScholarPubMed
Barthelemy-Brichant, N, Bosquée, L, Cataldo, D et al. Increased IL-6 and TGF-β1 concentrations in bronchoalveolar lavage fluid associated with thoracic radiotherapy. Int J Radiat Oncol Biol Phys 2004; 58: 758–767.CrossRefGoogle ScholarPubMed
Resnikoff, M, Brien, T, Vincent, PA et al. Lung matrix incorporation of plasma fibronectin reduces vascular permeability in postsurgical bacteremia. Am J Phys 1999; 277: L749–L759.Google ScholarPubMed
Cox, JD, Stetz, J, Pajak, TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995; 31; 1341–1346.CrossRefGoogle ScholarPubMed
Shanker, G, Olson, D, Bone, R, Sawhney, R. Regulation of extracellular matrix proteins by transforming growth factor β1 in cultured pulmonary endothelial cells. Cell Biol Int 1999; 23: 61–72.CrossRefGoogle ScholarPubMed
Nishioka, A, Ogawa, Y, Inomata, T, Maeda, T, Seguchi, H. Fibronectin expression in cancer tissues from patients undergoing radiation therapy. Histol Histopath 1993; 8: 457–462.Google ScholarPubMed